DelveInsight’s “Lyme Disease Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth analysis of Lyme disease, market, and clinical development in Lyme disease. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the Lyme disease market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover which therapies are expected to grab the major Lyme disease market share @ https://www.delveinsight.com/sample-request/lyme-disease-ld-market
Key Takeaways from the Lyme Disease Market Report
- The highest incidence of Borrelia infection causing Lyme disease is observed in children aged 5–15 years and adults over 50 years.
- In the UK, the age distribution of lyme disease shows the highest incidence in the 30–49 and 50–69 year age groups
- According to the Centers for Disease Control and Prevention, approximately 476,000 Americans are diagnosed and treated for Lyme disease each year with at least a further 130,000 cases in Europe.
- In Germany, the incidence of Lyme borreliosis was estimated at 37.2 cases per 100,000 person-years.
- Of the reported Lyme disease cases, 58% occurred in men.
- According to the Infectious Agents Surveillance Report, the incidence rate of lyme disease per 100,000 people in Japan was 0.008.
- The leading Lyme Disease Companies such as Pfizer, Sun Pharma, Novartis, Mayne Pharma, GlaxoSmithKline, Lupin Pharmaceuticals, Orion Crp., Perrigo Company, Chartwell Pharma, Almirall, and others.
- Promising Lyme Disease Therapies such as VLA15, mRNA-1975, TP-05, mRNA-1982, and others.
Learn more about the Lyme disease treatment options @ Lyme Disease Treatment Market
Lyme Disease Epidemiology Segmentation in the 7MM
- Incident cases of Lyme Disease
- Gender-specific incident cases of Lyme Disease
- Age-specific incident cases of Lyme Disease
- Treatable cases of Lyme Disease
Download the report to understand which factors are driving Lyme Disease Epidemiology Trends @ Lyme Disease Prevalence
Lyme Disease Emerging Drugs
- VLA15: Valneva and Pfizer
VLA15 is an investigational multivalent recombinant protein vaccine targeting six serotypes of Borrelia commonly associated with lyme disease in the United States and Europe. It acts by inducing antibodies against outer surface protein A (OspA), which is expressed by the bacterium within the tick; blocking OspA prevents transmission to humans. VLA15 is the most advanced Lyme disease vaccine candidate currently in clinical development. Pfizer, in partnership with Valneva, plans to submit a BLA to the FDA and a MAA to the EMA in 2026, pending positive trial outcomes. The vaccine received FDA Fast Track Designation in 2017.
- TP-05: Tarsus Pharmaceuticals
TP-05 is an oral systemic formulation of lotilaner under development for the prevention of Lyme disease, believed to be the only non-vaccine, drug-based preventive therapy in progress that targets and kills infected tick vectors before they can transmit Borrelia bacteria. Designed to rapidly achieve systemic blood levels of lotilaner, a well-characterized anti-parasitic agent it offers on demand protection and is currently being assessed in a Phase IIa trial according to the company’s pipeline.
Lyme Disease Market Outlook
The current preventive landscape for Lyme disease is largely dominated by vaccine-based approaches, with no approved drug-based prophylaxis available. TP-05, an oral systemic formulation of lotilaner, represents a novel market entrant and is believed to be the only non-vaccine, drug-based candidate in development targeting infected tick vectors before they can transmit Borrelia bacteria. Designed to rapidly achieve systemic blood levels of lotilaner, a well-characterized anti-parasitic agent, TP-05 offers on-demand protection and is currently in Phase IIa clinical evaluation. The introduction of such an innovative therapeutic has the potential to reshape the Lyme disease prevention market by addressing unmet needs in populations where vaccination may be unsuitable or unavailable, thereby expanding prevention options and potentially driving market growth in the coming years.
To know more about Lyme disease treatment guidelines, visit @ Lyme Disease Management
Lyme Disease Market Dynamics
The dynamics of the Lyme disease are expected to change in the coming years. The increasing awareness about Lyme disease among both healthcare professionals and the general public serves as a significant driver. This heightened awareness has led to early diagnosis and treatment, propelling the demand for diagnostic tests and medications. Additionally, advancements in diagnostic technologies and the development of novel treatment options are fostering Lyme disease market growth.
Lyme Disease Treatment Landscape
Most cases of lyme disease respond well to a 10–14 day course of antibiotics, with early treatment usually resulting in rapid and complete recovery. Commonly prescribed agents include doxycycline, amoxicillin, and cefuroxime axetil, with the choice of regimen guided by clinical presentation, patient age, allergy profile, pregnancy status, and other individual factors. Prompt diagnosis and timely initiation of therapy are critical to preventing progression to more severe disease. While routine antibiotic use after tick bites is not recommended, a single prophylactic dose of doxycycline may be considered in high-risk situations, such as bites acquired in areas of high lyme disease prevalence. Decisions regarding prophylaxis should follow established clinical guidelines and be informed by epidemiological context. Lyme disease treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the Lyme disease market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Lyme disease market growth.
Learn more about the FDA-approved drugs for Lyme disease @ Drugs for Lyme Disease Treatment
Scope of the Lyme Disease Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Lyme Disease Companies- Pfizer, Sun Pharma, Novartis, Mayne Pharma, GlaxoSmithKline, Lupin Pharmaceuticals, Orion Crp., Perrigo Company, Chartwell Pharma, Almirall, and others.
- Lyme Disease Therapies- VLA15, mRNA-1975, TP-05, mRNA-1982, and others.
- Lyme Disease Therapeutic Assessment: Lyme Disease current marketed and emerging therapies
- Lyme Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Lyme Disease Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Lyme Disease Market Access and Reimbursement
Discover more about Lyme disease drugs in development @ Lyme Disease Clinical Trials
Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary of Lyme Disease
4. Key Events of Lyme Disease
5. Epidemiology and Market Forecast Methodology
6. Lyme disease: Market Overview at a Glance
8. Patient Journey of Lyme Disease
9. Epidemiology and Patient Population of Lyme Disease
10. Emerging Drugs
11. Lyme disease: Seven Major Market Analysis
12. Unmet Needs of Lyme Disease
13. SWOT Analysis of Lyme Disease
14. KOL Views of Lyme Disease
15. Market Access and Reimbursement of Lyme Disease
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
